Drug may shrink kidney tumors, allowing less invasive surgery
NCT ID NCT03438708
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether taking the drug axitinib for 8 weeks before surgery can shrink kidney tumors in people with clear cell renal cell carcinoma. The goal is to make partial nephrectomy (removing only the tumor) possible for patients whose tumors are too complex for this surgery otherwise. About 22 participants with localized disease and imperative need for kidney preservation are being studied.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Axitinib (Inlyta) oral tablet
What this could lead to
If successful, this approach could allow more patients with complex kidney tumors to have partial nephrectomy instead of full kidney removal, preserving kidney function.
What could go wrong
This is a small, early-phase study with only 22 participants, so results may not apply to everyone. Axitinib can cause side effects like high blood pressure and fatigue, and the tumor may not shrink enough to change surgery options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States